NCT05225584 - Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions

Non Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)Large Granular Lymphocytic Leukemia (LGL-L)T-cell Prolymphocytic Leukemia (T-PLL)Solid Tumors

Interventions

DRUG

KT-333

KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.

Trial Locations (13)

10467

Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, The Bronx

19104

Abramson Cancer Center of the University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

22903

University of Virginia, Emily Couric Cancer Center, Charlottesville

40207

Norton Cancer Institute, Louisville

45219

The Christ Hospital Cancer Center, Cincinnati

48202

Henry Ford Hospital, Detroit

77030

MD Anderson Cancer Center, Houston

98195

University of WA/Seattle Cancer Care Alliance, Seattle

92868-3201

UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange

07601

Hackensack University Medical Center, John Theurer Cancer Center, Hackensack

43210-1240

Ohio State University Wexner Medical Center, Columbus

02903

Rhode Island Hospital, Providence